_:n3ac5704bbadc44509231089c8e2ee775xb0
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>
<http://schema.org/SearchAction>
<https://fr.oneamyloidosisvoice.com/news-meeting/zentalis-pharmaceuticals-announces-first-patient-dosed-potentially-registrational-phase-1-2-bcl-2-inhibitor-zn-d5-relapsed-refractory-light-chain-amyloidosis/>